Restless Legs Syndrome

Restless Legs Syndrome

Global Restless Legs Syndrome Market to Reach US$811.8 Million by 2030

The global market for Restless Legs Syndrome estimated at US$637.7 Million in the year 2023, is expected to reach US$811.8 Million by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. Medication & Devices, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$562.9 Million by the end of the analysis period. Growth in the Surgery segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$173.7 Million While China is Forecast to Grow at 6.8% CAGR

The Restless Legs Syndrome market in the U.S. is estimated at US$173.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$169.5 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Key Trends and Drivers

Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease, is a neurological disorder characterized by an uncontrollable urge to move the legs, typically due to unpleasant sensations described as crawling, tingling, or burning. The symptoms generally occur during periods of rest or inactivity, particularly at night, and can severely disrupt sleep and reduce quality of life. RLS affects approximately 5 to 10% of adults in the U.S., with a higher prevalence in women and older adults. The exact cause of RLS is unknown, but it is believed to be associated with imbalances in dopamine, a neurotransmitter that regulates muscle movement, and possibly iron deficiency. The condition can be idiopathic (having no identified cause) or secondary to other conditions such as pregnancy, iron deficiency, or renal failure.

Treatment for RLS typically involves a combination of lifestyle changes, pharmacological treatments, and sometimes iron supplementation if deficiency is present. Lifestyle interventions include maintaining regular sleep patterns, exercising moderately, and avoiding caffeine and alcohol. Medications used are mainly dopaminergic agents that increase dopamine effects, such as pramipexole and ropinirole, but can also include gabapentin and opioids for more severe cases. While these treatments do not cure RLS, they significantly alleviate symptoms and improve sleep and quality of life. However, long-term use of dopaminergic drugs can lead to augmentation—a condition where symptoms become worse than before treatment. This paradoxical effect poses a significant challenge in chronic RLS management, necessitating periodic evaluation and adjustment of therapy.

The growth in the Restless Legs Syndrome market is driven by several factors including heightened awareness and better diagnostic practices which increase the identification and reporting of RLS cases. Advances in neurology and sleep medicine contribute to improved understanding and treatments, enhancing market growth. An aging global population prone to neurological disorders also expands the patient base for RLS treatments. Additionally, ongoing research into the pathophysiology of RLS promises the development of more targeted therapies, potentially reducing the risk of augmentation seen with current dopaminergic treatments. The market benefits from increased healthcare spending and expanding reimbursement policies for sleep disorders, encouraging the adoption of both pharmacologic and non-pharmacologic therapies. Moreover, digital health innovations, like wearable devices monitoring sleep and movement, are becoming integral in managing RLS, offering new growth opportunities for technology developers and healthcare providers alike. As the landscape of RLS treatment evolves with these advancements, the market is expected to see sustained growth, improving outcomes for patients worldwide.

Select Competitors (Total 86 Featured) -

• Azurity Pharmaceuticals, Inc.
• Boehringer Ingelheim International GmbH
• Emalex Biosciences, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Relegs BV
• UCB SA

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.